Boundless Bio, Inc.

Healthcare · Biotechnology · United States

Last price 2.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 56.18M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel ...